The company is reassuring investors that a new investigation into its billing practices isn't a big deal.
Looking for bargains in the sector best positioned to ride aging demographic trends? These five are screaming buys.
The smoke is beginning to clear, and one Wall Street investment bank likes what it sees.
Acadia's newly approved Parkison's disease drug could trigger a buyout. Here's why.
A collection of underperforming stocks held by Soros Fund Management that could be set to bounce strongly.
Achillion Pharmaceuticals, Ophthotech Corp., and Kite Pharmaceuticals shares could move wildly because of upcoming trial data.
Billionaire money managers reduced their holdings in these popular stocks last quarter, but was it a smart move?
Offhand comments from Abbott's CEO, and a confusing statement from Alere makes a pending acquisition doubtful.
The biotech's numbers are meaningless, but an update on one of its programs sent the stock down.
Less-than-convincing comments from acquirer Abbott Labs are causing a sell-off.